top of page
Our Pipeline
We are building a pipeline of best-in-class engineered regulatory T cell (Treg) therapies for Inflammatory Disorders
Bastion Therapeutics' HQ has officially closed. After a challenging and rewarding journey over the past 2 years, we’ve made the difficult decision to close our doors. Our lab has been emptied, and the team is unfortunately having to move on to new paths.
Our Pipeline
Bastion Therapeutics is rapidly advancing its early programmes towards the clinic. Our chosen indications are based on the clear unmet medical need and a strong rationale of where Tregs will have a significant impact addressing the root cause of the disease.
Programme
Discovery
Preclinical
IND Enabling
Clinical
Product
Neuro
Inflammation
BTx-001
Peripheral Inflammation
BTx-002
Undisclosed Programmes
BTx-XXX
Bastion Therapeutics' HQ has officially closed. After a challenging and rewarding journey over the past 2 years, we’ve made the difficult decision to close our doors. Our lab has been emptied, and the team is unfortunately having to move on to new paths.
Bastion Therapeutics' HQ has officially closed. After a challenging and rewarding journey over the past 2 years, we’ve made the difficult decision to close our doors. Our lab has been emptied, and the team is unfortunately having to move on to new paths.
bottom of page